PMID- 28752663
OWN - NLM
STAT- MEDLINE
DCOM- 20180717
LR  - 20230829
IS  - 1538-7836 (Electronic)
IS  - 1538-7836 (Linking)
VI  - 15
IP  - 9
DP  - 2017 Sep
TI  - Platelet production from induced pluripotent stem cells.
PG  - 1717-1727
LID - 10.1111/jth.13736 [doi]
AB  - Ex vivo production of human platelets has been pursued as an alternative measure 
      to resolve limitations in the supply and safety of current platelet transfusion 
      products. To this end, induced pluripotent stem cells (iPSCs) are considered an 
      ideal global source, as they are not only pluripotent and self-renewing, but are 
      also available from basically any person, have relatively few ethical issues, and 
      are easy to manipulate. From human iPSCs, megakaryocyte (MK) lines with robust 
      proliferation capacity have been established by the introduction of specified 
      sets of genes. These expandable MKs are also cryopreservable and thus would be 
      suitable as master cells for good manufacturing practice (GMP)-grade production 
      of platelets, assuring availability on demand and safety against blood-borne 
      infections. Meanwhile, developments in bioreactors that physically mimic the in 
      vivo environment and discovery of substances that promote thrombopoiesis have 
      yielded competent platelets with improved efficiency. The derivation of platelets 
      from iPSCs could further resolve transfusion-related alloimmune complications 
      through the manufacturing of autologous products and human leukocyte antigen 
      (HLA)-compatible platelets from stocked homologous HLA-type iPSC libraries or by 
      manipulation of HLAs and human platelet antigens (HPAs). Considering these key 
      advances in the field, HLA-deleted platelets could become a universal product 
      that is manufactured at industrial level to safely fulfill almost all demands. In 
      this review, we provide an overview of the ex vivo production of iPSC-derived 
      platelets toward clinical applications, a production that would revolutionize the 
      blood transfusion system and lead the field of iPSC-based regenerative medicine.
CI  - (c) 2017 International Society on Thrombosis and Haemostasis.
FAU - Sugimoto, N
AU  - Sugimoto N
AD  - Department of Clinical Application, Center for iPS Cell Research and Application, 
      Kyoto University, Kyoto, Japan.
FAU - Eto, K
AU  - Eto K
AD  - Department of Clinical Application, Center for iPS Cell Research and Application, 
      Kyoto University, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170728
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
SB  - IM
MH  - Animals
MH  - Bioreactors
MH  - *Blood Platelets/immunology/metabolism
MH  - Cell Culture Techniques
MH  - Cell Line
MH  - Cell Lineage
MH  - Cell Proliferation
MH  - Humans
MH  - Induced Pluripotent Stem Cells/immunology/metabolism/*transplantation
MH  - Phenotype
MH  - Platelet Transfusion/adverse effects/*methods
MH  - Regenerative Medicine/instrumentation/*methods
MH  - *Thrombopoiesis
MH  - Transfusion Reaction/prevention & control
OTO - NOTNLM
OT  - bioreactors
OT  - blood platelets
OT  - induced pluripotent stem cells
OT  - megakaryocytes
OT  - transfusion reaction
EDAT- 2017/07/29 06:00
MHDA- 2018/07/18 06:00
CRDT- 2017/07/29 06:00
PHST- 2017/07/29 06:00 [pubmed]
PHST- 2018/07/18 06:00 [medline]
PHST- 2017/07/29 06:00 [entrez]
AID - S1538-7836(22)00850-9 [pii]
AID - 10.1111/jth.13736 [doi]
PST - ppublish
SO  - J Thromb Haemost. 2017 Sep;15(9):1717-1727. doi: 10.1111/jth.13736. Epub 2017 Jul 
      28.